Demographics and clinical characteristics of patients with IMID and controls
| Trial arm | Autoimmune disease group | Controls | Total | |
| Withhold therapy | Continue therapy | Controls | ||
| N | 82 | 99 | 59 | 240 |
| Vaccine | ||||
| CHadOx1nCov-19 (AstraZeneca) | 34 (41.5) | 47 (47.5) | 31 (52.5) | 112 (46.7) |
| BNT162b2 (Pfizer) | 48 (58.5) | 52 (52.5) | 28 (47.5) | 128 (53.3) |
| Sex | ||||
| Female | 60 (73.2) | 65 (66.3) | 33 (59.6) | 158 (66.4) |
| Male | 22 (26.8) | 33 (33.7) | 25 (43.1) | 80 (33.6) |
| BMI | 29.2 (7.1) | 28.8 (6.1) | 26.2 (5.0) | 28.3 (6.3) |
| Ethnicity | ||||
| African-American or black | 1 (1) | 1 (1) | 1 (1.7) | 3 (1.3) |
| Arabic | 0 (0) | 1 (1) | 0 (0) | 1 (0.4) |
| Asian | 8 (10) | 8 (8) | 14 (24.1) | 30 (12.7) |
| Indian | 2 (2.5) | 3 (3) | 1 (1.7) | 6 (2.5) |
| Indigenous | 2 (2.5 | 3 (3) | 0 (0) | 5 (2.1) |
| White | 66 (82.5) | 83 (84) | 40 (69) | 189 (79.8) |
| Other | 1 (0) | 0 (0) | 2 (3.4) | 3 (1.3) |
| Age | 55.4 (12.6) | 53.3 (14.4) | 54.4 (12.6) | 54.2 (13.3) |
| Smoking status | ||||
| Non-smoker | 55 (67.1) | 72 (73.5) | 48 (84.2) | 175 (73.8) |
| Current smoker | 9 (11.0) | 7 (7.1) | 5 (8.8) | 21 (8.9) |
| Ex-smoker | 18 (22.0) | 19 (19.4) | 4 (7.0) | 41 (17.3) |
| Medication class | ||||
| csDMARD | 26 (31.7) | 32 (32.3) | n/a | 58 (32.0) |
| bDMARD | 26 (31.7) | 37 (37.4) | n/a | 63 (34.8) |
| tsDMARD | 30 (36.6) | 30 (30.3) | n/a | 60 (33.2) |
| Autoimmune disease | ||||
| Ankylosing spondylitis | 6 (7.3) | 13 (13.1) | n/a | 19 (10.5) |
| Crohn’s disease | 1 (1.2) | 1 (1.0) | n/a | 2 (1.1) |
| Psoriatic arthritis | 27 (32.9) | 26 (26.3) | n/a | 53 (29.3) |
| Rheumatoid arthritis | 44 (53.7) | 53 (53.5) | n/a | 97 (53.6) |
| SLE/Sjögren's/CTD | 3 (3.7) | 2 (2.0) | n/a | 5 (2.8) |
| Ulcerative colitis | 0 (0) | 2 (2.0) | n/a | 2 (1.1) |
| Other | 1 (1.2) | 2 (2.0) | n/a | 3 (1.7) |
All data are n (%) or mean (SD) unless otherwise indicated.
bDMARD, biologic DMARD; BMI, body mass index; csDMARD, conventional synthetic DMARD; CTD, connective tissue disease; DMARD, disease-modifying antirheumatic drug; IMID, immune-mediated inflammatory disease; n/a, not available; SLE, systemic lupus erythematosus; tsDMARD, targeted synthetic DMARD.